CAMP Key Statistics, Chart & Performance
The current stock price of CAMP is 6 USD. In the past month the price increased by 84.62%. In the past year, price increased by 21.21%.
CAMP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.27 | 405.28B | ||
| AMGN | AMGEN INC | 14.98 | 176.43B | ||
| GILD | GILEAD SCIENCES INC | 14.85 | 150.87B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.04 | 114.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.25 | 81.59B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 784.65 | 52.87B | ||
| INSM | INSMED INC | N/A | 37.77B | ||
| NTRA | NATERA INC | N/A | 31.58B | ||
| BIIB | BIOGEN INC | 10.62 | 26.09B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.82 | 21.39B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.31B |
Related stock screener links
About CAMP
Company Profile
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
Company Info
CAMP4 THERAPEUTICS CORP
One Kendall Square, Bldg 1400 West 3rd Floor
Cambridge MASSACHUSETTS 92618 US
CEO: Jeffery Gardner
Employees: 55
Phone: 16176518867
CAMP4 THERAPEUTICS CORP / CAMP FAQ
What does CAMP do?
CAMP4 Therapeutics Corp. operates as a biotechnology company which engages in the discovery of treatment options for patients. The company is headquartered in Cambridge, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2024-10-11. The firm is focused on the discovery and development of regulatory RNA-based therapeutics with the goal of upregulating gene expression and restoring healthy protein levels to treat a range of genetic diseases. The company is leveraging its RAP Platform to advance a pipeline of programs focused on metabolic and central nervous system (CNS) disorders with validated disease biology and potential market opportunities due to the significant unmet need of affected patients. Its lead product candidate, CMP-CPS-001, has the potential to be the first disease-modifying therapy for the treatment of urea cycle disorders. CMP-CPS-001 is designed to improve urea cycle activity by amplifying expression of CPS1, a key enzyme that catalyzes the first step of the urea cycle, by binding to a CPS1-specific regRNA. Its CNS development program, CMP-SYNGAP, is focused on addressing the underlying cause of SYNGAP1-related disorders.
What is the stock price of CAMP4 THERAPEUTICS CORP today?
The current stock price of CAMP is 6 USD. The price decreased by -2.12% in the last trading session.
What is the dividend status of CAMP4 THERAPEUTICS CORP?
CAMP does not pay a dividend.
How is the ChartMill rating for CAMP4 THERAPEUTICS CORP?
CAMP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of CAMP4 THERAPEUTICS CORP (CAMP) based on its PE ratio?
CAMP4 THERAPEUTICS CORP (CAMP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.62).
Can you provide the ownership details for CAMP stock?
You can find the ownership structure of CAMP4 THERAPEUTICS CORP (CAMP) on the Ownership tab.
Can you provide the short interest for CAMP stock?
The outstanding short interest for CAMP4 THERAPEUTICS CORP (CAMP) is 1.22% of its float.
CAMP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to CAMP. When comparing the yearly performance of all stocks, CAMP is one of the better performing stocks in the market, outperforming 94.98% of all stocks.
CAMP Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CAMP. While CAMP seems to be doing ok healthwise, there are quite some concerns on its profitability.
CAMP Financial Highlights
Over the last trailing twelve months CAMP reported a non-GAAP Earnings per Share(EPS) of -4.62. The EPS increased by 79.75% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -61.48% | ||
| ROE | -90.54% | ||
| Debt/Equity | 0 |
CAMP Forecast & Estimates
12 analysts have analysed CAMP and the average price target is 8.93 USD. This implies a price increase of 48.75% is expected in the next year compared to the current price of 6.
For the next year, analysts expect an EPS growth of 70.71% and a revenue growth 2386.14% for CAMP